3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Hodgkin Disease
1
Hematologic Diseases
1
Endometrial Neoplasms
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
2
Paclitaxel
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
sacituzumab govitecan
1
pegfilgrastim
1
atezolizumab
1
Gemcitabine
1
Filgrastim
1
Epirubicin
1
Doxorubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Triple Negative Breast Neoplasms
×
Doxorubicin
×
Clear all
NCT03036488
2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3
Completed
1,174 enrolled
1 FDA